

# Giorgia Gurioli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9113777/publications.pdf>

Version: 2024-02-01

52  
papers

1,458  
citations

516710

16  
h-index

330143

37  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2444  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. <i>Molecular Oncology</i> , 2022, 16, 538-548.	4.6	4
2	Plasma tumor ctDNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. <i>International Journal of Cancer</i> , 2022, 150, 1166-1173.	5.1	4
3	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. <i>BMC Medicine</i> , 2022, 20, 48.	5.5	8
4	Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. <i>Cancers</i> , 2022, 14, 2219.	3.7	5
5	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103199.	4.4	16
6	An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 631-640.	3.1	4
7	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	6.4	13
8	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	2.8	4
9	Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 716467.	2.8	8
10	Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications. <i>Cancers</i> , 2021, 13, 5223.	3.7	10
11	Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. <i>Frontiers in Oncology</i> , 2020, 10, 567809.	2.8	5
12	Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 565857.	2.8	14
13	Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 982-987.	6.4	22
14	Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2091-2099.	1.8	8
15	Genome-wide plasma DNA methylation features of metastatic prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1991-2000.	8.2	68
16	Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>Prostate</i> , 2019, 79, 1211-1220.	2.3	17
17	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	1.3	6
18	Plasma Androgen Receptor in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1719.	3.7	13

#	ARTICLE	IF	CITATIONS
19	Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2569.	4.1	18
20	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	2.8	29
21	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	8
22	Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management. <i>Future Oncology</i> , 2019, 15, 1347-1352.	2.4	4
23	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. <i>Cancers</i> , 2019, 11, 1935.	3.7	21
24	Epigenetic Characterization of Cell-Free DNA. <i>Methods in Molecular Biology</i> , 2019, 1909, 129-135.	0.9	2
25	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	1.9	64
26	Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3020-3020.	1.6	3
27	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 203-203.	1.6	1
28	Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5039-5039.	1.6	1
29	GSTP1 methylation in cancer: a liquid biopsy biomarker?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 702-717.	2.3	40
30	Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. <i>BMC Cancer</i> , 2018, 18, 1267.	2.6	12
31	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 15442.	3.3	21
32	Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). <i>Eur Urol</i> 2018;74:283â€“91. <i>European Urology</i> , 2018, 74, e67-e68.	1.9	2
33	Carcinosarcoma of the prostate: case report with molecular and histological characterization. <i>International Journal of Biological Markers</i> , 2018, 33, 540-544.	1.8	12
34	Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5074-5074.	1.6	2
35	Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. <i>Annals of Oncology</i> , 2017, 28, 1508-1516.	1.2	213
36	Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 15541.	3.3	11

#	ARTICLE	IF	CITATIONS
37	Serum and Plasma Copy Number Detection Using Real-time PCR. Journal of Visualized Experiments, 2017, , ,	0.3	3
38	Vitamin D status among long-term survivors of testicular cancer. Oncotarget, 2017, 8, 36780-36786.	1.8	14
39	Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.. Journal of Clinical Oncology, 2017, 35, 160-160.	1.6	0
40	Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, 5060-5060.	1.6	1
41	<i>GSTP1</i> Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. Disease Markers, 2016, 2016, 1-6.	1.3	68
42	Cell-free DNA as a diagnostic marker for cancer: current insights. OncoTargets and Therapy, 2016, Volume 9, 6549-6559.	2.0	104
43	Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. Journal of Translational Medicine, 2016, 14, 249.	4.4	16
44	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs, 2016, 30, 263-273.	4.6	22
45	The potential use of urine cell free DNA as a marker for cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1283-1290.	3.1	39
46	Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview. Molecular Diagnosis and Therapy, 2016, 20, 1-12.	3.8	5
47	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget, 2016, 7, 37839-37845.	1.8	69
48	Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer. Translational Cancer Research, 2016, 5, S803-S808.	1.0	5
49	Circulating <i>AR</i> copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel.. Journal of Clinical Oncology, 2016, 34, e16583-e16583.	1.6	0
50	Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. Disease Markers, 2015, 2015, 1-6.	1.3	40
51	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. Science Translational Medicine, 2015, 7, 312re10.	12.4	366
52	Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer. International Journal of Molecular Sciences, 2014, 15, 12458-12468.	4.1	13